Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced it has been awarded a $500,000 grant from the Western Australian Government to accelerate the commercialisation of its world-first blood test for endometriosis, a condition affecting one in nine women globally.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) Managing Director Dr. Richard Lipscombe is interviewed about the most recent Quarterly Report and the pipeline of precision diagnostic tests in commercialisation phase.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, announced the following update on its business activities for the three months to 30 September 2025 and subsequent to the period end.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce it has expanded its collaborative research agreement with the University of Melbourne and the Royal Women's Hospital.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce the appointment of Ms Vicki Robinson to its Board as an independent non-executive director, effective 14 October 2025.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce the appointment of David Wood as Joint Company Secretary for Proteomics International, effective today.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce its latest results on its first-in-class blood test for esophageal adenocarcinoma, PromarkerEso, are being presented today at the 21st ISDE World Congress for Esophageal Diseases, in Brisbane, Australia, 18-20 September 2025.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce it has been granted ISO 15189 certification for its Australian laboratory operations.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics and precision medicine, today announces a planned Board and Management transition.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce new results showing its first-in-class PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma (EAC) with high accuracy.
Correction - Notice of Extraordinary General Meeting/Proxy
Notice of Extraordinary General Meeting/Proxy Form
Investor Presentation - JMM Biotech Forum
Interim Financial Report and Appendix 4D
